Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Non-cash Items: 2013-2024

Historic Non-cash Items for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Dec 2024 value amounting to $95.3 million.

  • Amphastar Pharmaceuticals' Non-cash Items fell 97.17% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.8 million, marking a year-over-year decrease of 97.17%. This contributed to the annual value of $95.3 million for FY2024, which is 70.87% down from last year.
  • According to the latest figures from FY2024, Amphastar Pharmaceuticals' Non-cash Items is $95.3 million, which was down 70.87% from $327.2 million recorded in FY2023.
  • In the past 5 years, Amphastar Pharmaceuticals' Non-cash Items registered a high of $327.2 million during FY2023, and its lowest value of $5.6 million during FY2022.
  • Moreover, its 3-year median value for Non-cash Items was $95.3 million (2024), whereas its average is $142.7 million.
  • Its Non-cash Items has fluctuated over the past 5 years, first skyrocketed by 5,793.94% in 2023, then slumped by 70.87% in 2024.
  • Amphastar Pharmaceuticals' Non-cash Items (Yearly) stood at $5.8 million in 2020, then decreased by 2.57% to $5.6 million in 2021, then fell by 1.00% to $5.6 million in 2022, then surged by 5,793.94% to $327.2 million in 2023, then plummeted by 70.87% to $95.3 million in 2024.